Pegfilgrastim Biosimilar Market, By Product Class (Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory Agents, and Other Product Classes), By Applications (Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Oncology, and Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI481121 | Publish Date: May 2023 | No. of Pages: 167

Global Pegfilgrastim Biosimilar Market Overview

Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, is PEGylated to create Pegfilgrastim. Amgen Inc originally introduced pegfilgrastim as Neulasta. Pegfilgrastim biosimilars were later introduced to the market. Pegfilgrastim is a supportive oncology medication used to treat neutropenia caused by chemotherapy and/or radiotherapy in cancer patients. With more than ten pegfilgrastim biosimilars on the market and another five in the works, the pegfilgrastim biosimilar size market is projected to grow in the future. On the whole, the COVID-19 pandemic has had a minor impact on the pegfilgrastim market. COVID-19 has sped up clinical trial processes in general, but it is not expected to have a significant impact on regulatory approval processes in the near future. The Global Pegfilgrastim Biosimilar Market accounted for US$ 2765 million in 2020 and is estimated to be US$ 16580.8 million by 2030 and is anticipated to register a CAGR of 19.8%.

Global Pegfilgrastim Biosimilar Market Dynamics

Academic and Research organizations in this industry through partnerships will drive the growth of the Market

Strategic alliances are helping companies in the pegfilgrastim biosimilar sector improve their product innovation. Companies are developing novel products and sharing skills and experience with other companies to maintain their place in an increasingly competitive market. While firms have traditionally partnered with one another as well as academic and research organisations in this industry through partnerships, in- or out-licensing agreements, this tendency has accelerated in recent years. Fulphila, produced jointly by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be authorised by the FDA in July 2018. Biocon Biologic Ltd. and the Clinton Health Access Initiative (CHAI) announced a collaboration deal in February 2021 to expand their lifesaving cancer biosimilars in more than 30 African and Asian countries. The collaboration represents a critical step forward in the delivery of sophisticated cancer medicines.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Pegfilgrastim Biosimilar Market Segmentation

                                                

 

                                                 Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

The Global Pegfilgrastim Biosimilar Market is segmented based on product class, application, distribution channel and region.

On the basis of Product Class, the Global Pegfilgrastim Biosimilar Market is segmented into Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory Agents, and Other Product Classes. Based on Application, the target market is segmented into Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Oncology, and Other Applications. Based on Distribution Channel, the target market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Insights:

 

                                                                                                                                Source: Prophecy Market Insights

                                            

On region the Global Pegfilgrastim Biosimilar Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Pegfilgrastim biosimilars market in North America is expected to grow at a considerable CAGR over the forecast period. The high frequency of chronic diseases, such as cancers, as well as increased investment in research and development activities by the key players, are the main drivers driving the expansion of the studied market in the region.  For instance, According to Globocon 2020, in 2020, there are 2,281,658 new cancer cases diagnosed in the United States, with 612,390 fatalities. Breast cancer had the greatest incidence of all malignancies, with 253,465 cases, followed by lung (227,875), prostate (209,512), and colon cancer (101,809). Furthermore, according to a study published in Biosimilar Development 2020, the majority of biosimilars are injectables that must be administered to patients by a clinician. Due to the high risk of SARS-CoV2 viral transmission, most hospitals and clinics in the United States have banned physical consultations.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2029

Market Segmentation

By Product Class- Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory Agents, and Other Product Classes

By Application– Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, Oncology, and Other Applications

By Distribution Channel- Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Pegfilgrastim Biosimilar Market report based on product class, application, distribution channel and region.

                                                    

Global Pegfilgrastim Biosimilar Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Pegfilgrastim Biosimilar Market Key Players

The market for pegfilgrastim biosimilars is very concentrated and competitive. This biosimilar was created by a number of small and large pharmaceutical businesses. Coherus Biosciences, Mylan N.V., Biocon, and Novartis AG are some of the major companies in the market (Sandoz). These firms have launched pegfilgrastim biosimilars and are bolstering their global market position with partnerships and collaborations. Pfizer Inc, Green Cross Corp, Accord Healthcare, Intas Pharmaceuticals Ltd, and Zydus Cadila are among the market's other participants. These companies are concentrating on strategic collaborations and partnerships, as well as research and development, in order to develop novel biosimilar platforms. Most of the market players are adopting various growth strategies, such as acquisitions, partnerships, and new product launches, to secure the position in the global market. For instance, in December 2020, Coherus filed FDA 351(K) application for its CHS-1420, a biosimilar of adalimumab, and the regulatory decision is expected by Q4 of 2021.

Global Pegfilgrastim Biosimilar Market Company Profile

  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Coherus Biosciences Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Mylan NV (Viatris Inc.)
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Samsung Bioepis Co. Ltd
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies

Global Pegfilgrastim Biosimilar Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Pegfilgrastim Biosimilar Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Product Class
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Pegfilgrastim Biosimilar Market, By Product Class, 2020 – 2030, (US$ Mn)
    • Overview                                   
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Monoclonal Antibodies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Recombinant Hormones
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Immuno modulators
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Anti-Inflammatory Agents
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Pegfilgrastim Biosimilar Market, By Application, 2020 – 2030, (US$ Mn)
    • Overview                                                
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Blood Disorders
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Growth Hormonal Deficiency
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Chronic and Autoimmune Disorders
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Oncology
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  7. Global Pegfilgrastim Biosimilar Market, By Distribution Channel, 2020 – 2030, (US$ Mn)
    • Overview                                   
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Online Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  8. Global Pegfilgrastim Biosimilar Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Product Class, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Product Class, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Product Class, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Product Class, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Product Class, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  10. Company Profiles
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Coherus Biosciences Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Mylan NV (Viatris Inc.)
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Samsung Bioepis Co. Ltd
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

Global Pegfilgrastim Biosimilar Market is segmented based on product class, application, distribution channel and region.

Academic and Research organizations in this industry through partnerships is major factor driving the market.

During the forecast period, North America is expected to dominate the market.

Coherus Biosciences, Mylan N.V., Biocon, and Novartis AG are some of the major companies in the market (Sandoz). These firms have launched pegfilgrastim biosimilars and are bolstering their global market position with partnerships and collaborations.